KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Gilead Sciences (GILD) Long-Term Deferred Tax (2016 - 2026)

Gilead Sciences filings provide 11 years of Long-Term Deferred Tax readings, the most recent being $2.0 billion for Q4 2025.

On a quarterly basis, Long-Term Deferred Tax fell 17.41% to $2.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 billion, a 17.41% decrease, with the full-year FY2025 number at $2.0 billion, down 17.41% from a year prior.
Long-Term Deferred Tax hit $2.0 billion in Q4 2025 for Gilead Sciences, down from $2.0 billion in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $2.7 billion in Q2 2025 to a low of $2.0 billion in Q4 2025.